SAGE רווח נקי למניה ב-12 החודשים האחרונים Sage Therapeutics Inc.

Sage Therapeutics, Inc. (SAGE) is transforming psychiatry by creating an innovative treatment system for insomnia and depression. The current annual net income per share on GURU.Markets reflects profit dynamics where the value -4.88 serves as the target level. Sage Therapeutics, Inc. (SAGE) is ramping up Zurzuvae sales and expanding its influence in neuropharmacology through a strategic alliance. Drug production relies on certified partner facilities and streamlined internal logistics.
פילוחים אנליטיים ודוחות נתונים של חברת Sage Therapeutics Inc (SAGE)

Investors must evaluate long-term earnings sustainability while excluding the impact of share issuances. This indicator is calculated as the ratio of total annual net income to the weighted average number of shares outstanding. Analyzing the trailing 12-month net income per share allows for tracking the impact of operating expenses on final profitability. An upward trend confirms management efficiency. This is critical for Sage Therapeutics, Inc. (SAGE), as a high dependence on third-party CMO manufacturers directly affects margins.